EO Care, Inc. Statement on Proposed Federal Register Change

EO Care, Inc. Statement on Proposed Federal Register Change by CMS Expanding Coverage for Hemp-Derived Cannabinoids

‍

As the leader in cannabinoid based symptom management for older adults, we applaud the Centers for Medicare & Medicaid Services (CMS) proposal to expand coverage for federally legal, hemp-derived cannabinoid-based products.

‍

At EO, we are uniquely positioned to meet the need of this new, covered cannabinoid care market:

‍

• Our federally legal, hemp-derived CBD and low-potency THC products are clinician-designed specifically for those who are are seeking to manage the symptoms of aging and cancer-related symptoms (such as pain, stress, sleep and reduced appetite). EO’s products are organic, 3rd-party tested and produced in GMP-certified facilities.

• Our free, HIPAA-compliant digital health platform is the only platform providing personalized, clinically responsible cannabis product, dose and use guidance at near infinite scale.

• Our products and care platform have already been tested  and validated via referring clinicians at leading hospitals and NCI-designated cancer centers.

• Our products and care platform have demonstrated clinical efficacy using broadly accepted PROMIS metrics as well as significant, Milliman-validated cost of care reductions.

‍

While the news from CMS heralds an important step forward, we now call on Congress to roll back or amend it’s contradictory, draconian decision to prohibit the vast majority of hemp-derived cannabinoid products starting in November 2026. As currently written, this prohibition will render the news from HHS and CMS largely moot, as the only products that would remain legal and potentially covered have few or no proven clinical benefits for older adults and those in cancer treatment. Consequently, the tens of millions of older adults benefitting from cannabinoid-based treatments would see those treatments terminated next year - or be forced to pursue unsafe, illicit remedies.

‍

Improved access to quality cannabinoid care and products will reduce healthcare costs and improve quality of life for older adults. It’s that simple. We look forward to continuing and expanding our work with all relevant government, clinical and payer stakeholders in order to provide the safest, most effective and accessible cannabinoid care possible.

‍

About EO Care, Inc.

‍

EO is the leader in cannabinoid-based symptom management. The company provides personalized, clinically responsible care through its unique, scalable digital health platform and affordable, medicalized and federally legal hemp-derived cannabinoid products. Board members, advisors and investors include Regina Benjamin, MD, MBA, former Surgeon General of the United States; Kristi Savacool, former CEO of AON Hewitt; and Bill Van Faasen, former CEO of Blue Cross Blue Shield Massachusetts. For more information, visit eo.care.

‍